Powder: -20°C for 3 years | In solvent: -80°C for 1 year
TPA-023B is an orally active and high-affinity agonist of the GABAA receptor α2/α3 subtype (Kis: 0.73 nM/2 nM) partial and an antagonist α1 subtype (Ki: 1.8 nM), has non-sedating anxiolytic-like properties.
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
2 mg | ¥ 2,890 | 5日内发货 | ||
25 mg | ¥ 10,600 | 6-8周 | ||
50 mg | ¥ 13,800 | 6-8周 | ||
100 mg | ¥ 17,500 | 6-8周 |
产品描述 | TPA-023B is an orally active and high-affinity agonist of the GABAA receptor α2/α3 subtype (Kis: 0.73 nM/2 nM) partial and an antagonist α1 subtype (Ki: 1.8 nM), has non-sedating anxiolytic-like properties. |
体外活性 | TPA-023B has high affinity for α5 subtype with Ki of 1.1 nM of human recombinant GABAA receptor, but over 1500-fold lower for the α4- and α6 containing subtypes (Ki > 1000 nM). In different regions of the CNS,TPA-023B also has a comparable affinity for native rat GABAA receptors (Ki of 0.32-0.99 nM in cerebellum, spinal cord and frontal cortex). TPA-023B antagonizes the ability of chlordiazepoxide to potentiate the GABA EC20-induced current in cells expressing the α1 subtype. More specifically, 3 μM chlordiazepoxide potentiates the GABA EC20 current by 105% and this effect could be reduced to 8% in the presence of 100 nM TPA-023B. |
体内活性 | Measured using an in vivo [3H]flumazenil binding assay,TPA-023B gives dose- and time-dependent occupancy of rat brain GABAA receptors, with 50% occupancy corresponding to a respective dose and plasma drug concentration of 0.09 mg/kg and 19 ng/mL. TPA-023B is anxiolytic in rodent and primate (squirrel monkey) models of anxiety (elevated plus maze, fear-potentiated startle,up to doses (10 mg/kg) corresponding to occupancy of greater than 99%. |
分子量 | 391.37 |
分子式 | C21H15F2N5O |
CAS No. | 425377-76-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
TPA-023B 425377-76-0 Others TPA 023B TPA023B Inhibitor inhibitor inhibit